Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7657656 | 0.89 | ELANE (0.37) | ELANECTRB1MCHR1 | |
| SCHEMBL6806600 | 0.88 | ELANE (0.37) | ELANECTRB1CYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL6500402 | 0.76 | ELANE (0.61) | ELANECTRB1CYP3A4CYP2D6 | |
| SCHEMBL6806250 | 0.73 | CTRB1 (0.41) | ELANECTRB1ALDH1A1MEN1KMT2A | |
| SCHEMBL6503996 | 0.70 | ELANE (0.60) | ELANECTRB1 | |
| SCHEMBL7840236 | 0.70 | ELANE (0.59) | ELANECTRB1 | |
| SCHEMBL7662984 | 0.69 | ELANE (0.37) | ELANECTRB1 | |
| SCHEMBL6806815 | 0.69 | CTRB1 (0.53) | ELANECTRB1 | |
| SCHEMBL7445651 | 0.69 | ELANE (0.58) | ELANECTRB1 | |
| SCHEMBL6499181 | 0.67 | ELANE (0.35) | ELANECTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683077-B2 | 4H-3,1-BENZOXAZIN-4-ONE COMPOUNDS OF GIVEN FORMULA; HERPES INFECTIONS; ASSEMBLIN PROTEASE INHIBITORS | G.D. SEARLE & CO. | 2004-01-27 | — | — | US | claimed |
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | G.D. SEARLE & CO. | 2003-01-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022895-A1 | 2-Amino-benzoxazinones for the treatment of viral infections | IFNAR1, IL4I1, HAX1 | ELANE 2176/4885CTRB1 2628/4885MCHR1 778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.